Study of Alloreactive Memory B Cells and Anti-HLA Antibodies in Adults Awaiting Kidney Transplantation

What this Trial Is About

This research aims to better understand how alloreactive memory B lymphocytes Bmem contribute to kidney transplant rejection in patients sensitized to HLA antigens. The study focuses on characterizing the diversity, behavior, and function of these B cells in people awaiting kidney transplantation. It compares patients with different levels of HLA immunization, including highly immunized, moderately immunized, and nafve patients without known immune-promoting events, to clarify their immune response patterns. Participants will have a single blood sample taken at enrollment to analyze their Bmem targeting specific HLA alleles. This analysis will use advanced single-cell techniques to study the B-cell receptor diversity, membrane markers, and gene expression profiles. The study includes three patient groups based on their incompatible graft rate IGR and HLA antibody profiles, aiming to distinguish differences in Bmem clonality and function. During the study, participants will provide one 50 ml blood sample as part of routine care. Researchers will assess the heterogeneity of alloreactive Bmem at enrollment, including phenotypic and transcriptional diversity, clonality, and mutation status. The main outcome is to measure the diversity of Bmem targeting HLA alloantigens. This pilot study will generate foundational data to guide future investigations of B-cell responses in kidney transplant rejection. The study is expected to continue until mid-2028.

Alloreactive Memory B Lymphocytes and Anti-HLA Sensitization